Investigation of Bacterial Infections Among Patients Treated With Umbilical Cord Blood–Derived Products Marketed as Stem Cell Therapies
Authors:
Open Access
- 7 October 2021
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 4 (10) , e2128615
Abstract
Many clinics marketing stem cell products as treatment for joint diseases, sports injuries, and chronic pain opened in recent years1,2 despite warnings from the US Food and Drug Administration (FDA) that stem cell products for these and other indications have not been proven safe or effective.3 Recently, there has been an increase in marketing of unapproved stem cell products to prevent and treat COVID-19.4,5 The only FDA-approved stem cell products are derived from umbilical cord blood and are used to treat certain cancers and disorders of the hematopoietic system, such as leukemias, lymphomas, and sickle cell disease.3,6,7 The FDA has not approved stem cell products to treat any other diseases or conditions, such as osteoarthritis or aging. Generally, an unapproved stem cell product should be administered to patients only if there is an Investigational New Drug Application (IND) in effect for that product with FDA.Keywords
This publication has 5 references indexed in Scilit:
- Notes from the Field: Infections After Receipt of Bacterially Contaminated Umbilical Cord Blood–Derived Stem Cell Products for Other Than Hematopoietic or Immunologic Reconstitution — United States, 2018MMWR. Morbidity and Mortality Weekly Report, 2018
- The FDA and the US Direct-To-Consumer Marketplace for Stem Cell Interventions: A Temporal AnalysisRegenerative Medicine, 2018
- Clarifying Stem-Cell Therapy’s Benefits and RisksNew England Journal of Medicine, 2017
- Selling Stem Cells in the USA: Assessing the Direct-to-Consumer IndustryCell Stem Cell, 2016
- 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care SettingsAmerican Journal of Infection Control, 2007